Perspective Therapeutics Announces Changes to the Board of
Heidi Henson was appointed to the Board of Directors and named Audit Committee Chair taking over from Rob Williamson, III, who will continue to serve as a...
Source: globenewswire.com
Respivant Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Respivant Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Respivant Sciences Today - Breaking & Trending Today
Perspective Therapeutics Announces Changes to the Board of Directors
Heidi Henson was appointed to the Board of Directors and named Audit Committee Chair taking over from Rob Williamson, III, who will continue to serve as a member of the CommitteeMichael McCormick... | May 15, 2023
Source: marketscreener.com
Global Idiopathic Pulmonary Fibrosis Market Report 2022 - Strategic Opportunities Windows and Assessment of Unmet Needs
/PRNewswire/ -- The "Global Idiopathic Pulmonary Fibrosis Market, By Therapy, Estimation & Forecast, 2017-2030" report has been added to...
Source: prnewswire.com
Global Idiopathic Pulmonary Fibrosis Market Report 2022 - Strategic Opportunities Windows and Assessment of Unmet Needs
/PRNewswire/ -- The "Global Idiopathic Pulmonary Fibrosis Market, By Therapy, Estimation & Forecast, 2017-2030" report has been added to...
Source: prnewswire.com
![Idiopathic Pulmonary Fibrosis Market Size anticipated to register growth at a CAGR of 16% during the forecast period [2020-2030] in the 7MM, estimates DelveInsight - Vimarsana News](https://vimarsana.com/images/vimarsana-bigimage.jpg)
Idiopathic Pulmonary Fibrosis Market Size anticipated to register growth at a CAGR of 16% during the forecast period [2020-2030] in the 7MM, estimates DelveInsight
Esbriet, and Ofev (tyrosine kinase inhibitors). Both drugs have been shown to slow the disease progression but do not significantly impact mortality. The surge in Idiopathic Pulmonary Fibrosis market size is due to an increase in the prevalence of IPF patients in the 7MM, along with promising assets such as RG 6354, Pamrevlumab, Of all the emerging therapies, the most anticipated product to launch is the RG 6354 (Roche). It has received Breakthrough Therapy Designation from the FDA. Apart from this, other products such as Pamrevlumab, , Ziritaxestat, GB0139, and others have demonstrat...
Source: prnewswire.com